Autopsy report · NCT04372979

Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.

“Reluctance of patients and physicians in this transfusion study setting. Blood products have expired. New variants have appeared since the plasma collection period. Some recent publications question the effectiveness of transfusion.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 9 months before it stopped.
• 18 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Direction Centrale du Service de Santé des Armées

Sponsor type

University, hospital or other

Conditions

COVID-19

Interventions

Transfusion of SARS-CoV-2 Convalescent Plasma.; Transfusion of standard Plasma.

Participants

18

Sites

4

Countries

France

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.